Langdon L. Miller

14.0k citations

65 papers · 7.6k indexed · 3 hit papers · h-index 29

Oncology top 0.5%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 1%
Genetics top 0.5%
Pathology and Forensic Medicine top 0.5%

Co-authors: Gary Elfring Paula K. Locker Nicoletta Pirotta Leonard B. Saltz John V. Cox Stephen P. Ackland Lee S. Rosen Charles D. Blanke
Topics: Cancer therapeutics and mechanisms (19 papers)Chronic Lymphocytic Leukemia Research (17 papers)Lung Cancer Research Studies (10 papers)
Cited by: Genetics Oncology Hepatology
Journals: New England Journal of Medicine The Lancet Journal of Clinical Oncology
Partner nations: United States Italy United Kingdom

In The Last Decade

Langdon L. Miller

65 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2000 2.4k citations Leonard B. Saltz, John V. Cox et al. New England Journal of Medicine profile →
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 465 citations Brian J. Lannutti, Albert S. Yu et al. Blood profile →
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers

Countries citing papers authored by Langdon L. Miller

Since Specialization

Citations

This map shows the geographic impact of Langdon L. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Langdon L. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Langdon L. Miller more than expected).

Fields of papers citing papers by Langdon L. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Langdon L. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Langdon L. Miller. The network helps show where Langdon L. Miller may publish in the future.

Co-authorship network of co-authors of Langdon L. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Langdon L. Miller. A scholar is included among the top collaborators of Langdon L. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Langdon L. Miller. Langdon L. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiabreakdown → 2011 ·Blood ·Julia Hoellenriegel,Sarah Meadows,Mariela Sivina,William G. Wierda,Hagop M. Kantarjian,Michael J. Keating,Neill A. Giese,Susan O’Brien,Albert S. Yu,Langdon L. Miller,Brian J. Lannutti,Jan A. Burger	442
2	Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis 2011 ·Journal of Cystic Fibrosis ·Eitan Kerem,Michael Wilschanski,(unknown),Thea Pugatsch,(unknown),Hannah Blau,Joseph Rivlin,David Shoseyov,A. Reha,S. Constantine,Temitayo Ajayi,Samit Hirawat,Gary Elfring,Stuart W. Peltz,Langdon L. Miller	11
3	Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis 2010 ·American Journal of Respiratory and Critical Care Medicine ·Isabelle Sermet‐Gaudelus,K. De Boeck,Georges Casimir,F. Vermeulen,Teresinha Leal,Agnès Mogenet,Delphine Roussel,Janine Fritsch,L. Hanssens,Samit Hirawat,(unknown),S. Constantine,A. Reha,Temitayo Ajayi,Gary Elfring,Langdon L. Miller	184
4	The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy 2009 ·Muscle & Nerve ·Craig M. McDonald,Erik Henricson,Jay J. Han,Richard T. Abresch,Alina Nicorici,Gary Elfring,(unknown),A. Reha,Samit Hirawat,Langdon L. Miller	283
5	Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial 2008 ·The Lancet ·Eitan Kerem,Samit Hirawat,S. Armoni,Yasmin Yaakov,David Shoseyov,Michael Cohen,Malka Nissim‐Rafinia,Hannah Blau,Joseph Rivlin,Micha Aviram,Gary Elfring,Valerie Northcutt,Langdon L. Miller,Batsheva Kerem,Michael Wilschanski	290
6	Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers 2007 ·The Journal of Clinical Pharmacology ·Samit Hirawat,Ellen Welch,Gary Elfring,Valerie Northcutt,Sergey Paushkin,Seongwoo Hwang,(unknown),Neil G. Almstead,William Ju,Stuart W. Peltz,Langdon L. Miller	188
7	A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors 2005 ·Cancer Chemotherapy and Pharmacology ·Henry C. Pitot,Alex A. Adjei,Joel M. Reid,Jeff A. Sloan,Philip J. Atherton,Joseph Rubin,Steven R. Alberts,Barbara A. Duncan,Louis Denis,Larry J. Schaaf,Donghua Yin,Amarnath Sharma,(unknown),Langdon L. Miller,Charles Erlichman	23
8	Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation 2003 ·Biology of Blood and Marrow Transplantation ·Charles Linker,Paolo Anderlini,Roger H. Herzig,Neal P. Christiansen,George Somlo,William Bensinger,Joseph W. Fay,Joseph P. Lynch,Lawrence T. Goodnough,Mark Ashby,Mark Benyunes,Dennie V. Jones,(unknown),Langdon L. Miller,Charles H. Weaver	24
9	Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen 2003 ·Cancer ·Timothy F. Cloughesy,Emese Filka,John G. Kuhn,(unknown),Fairooz F. Kabbinavar,Henry S. Friedman,Langdon L. Miller,Gary Elfring	88
10	Irinotecan in the treatment of glioma patients 2003 ·Cancer ·Jan C. Buckner,Joel M. Reid,K C Wright,Scott H. Kaufmann,Charles Erlichman,Matthew M. Ames,(unknown),Judith R. OʼFallon,(unknown),Langdon L. Miller	33
11	Irinotecan (CPT-11) in Triplet Combinations in Patients with Advanced Non–Small-Cell Lung Cancer: A Review and Report of a Phase I/II Trial 2001 ·Clinical Lung Cancer ·Mark A. Socinski,Alan B. Sandler,Langdon L. Miller,Paula K. Locker,(unknown),Gary Elfring,Valerie K. Israel,Nicoletta Pirotta,Ronald B. Natale	3
12	Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients 2000 ·Drug Metabolism and Disposition ·J. Greg Slatter,Larry J. Schaaf,James P. Sams,Kenneth L. Feenstra,(unknown),Paul A. Bombardt,K. S. Cathcart,(unknown),Laura Pearson,Linda D. Compton,Langdon L. Miller,David Baker,(unknown),Raymond S. Lord	241
13	Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancerbreakdown → 2000 ·New England Journal of Medicine ·Leonard B. Saltz,John V. Cox,Charles D. Blanke,Lee S. Rosen,Louis Fehrenbacher,Malcolm J. Moore,Jean A. Maroun,Stephen P. Ackland,Paula K. Locker,Nicoletta Pirotta,Gary Elfring,Langdon L. Miller	2368
14	Treatment with Tumor Necrosis Factor-α and Granulocyte–Macrophage Colony-Stimulating Factor Increases Epidermal Langerhans' Cell Numbers in Cancer Patients 1999 ·Clinical Immunology ·John E. Janik,Langdon L. Miller,William C. Kopp,Dennis D. Taub,Harry Dawson,(unknown),(unknown),Brendan D. Curti,Kevin C. Conlon,Barbara K. Dunn,(unknown),Robert L. Ullrich,W. Gregory Alvord,Barry L. Gause,Dan L. Longo	19
15	A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma 1999 ·Cancer ·Mace L. Rothenberg,John V. Cox,Russell F. DeVore,John D. Hainsworth,Richard Pazdur,Saul E. Rivkin,John S. Macdonald,Charles E. Geyer,John F. Sandbach,Daniel L. Wolf,J. Scott Mohrland,Gary Elfring,Langdon L. Miller,Daniel D. Von Hoff	162
16	Phase II study of adozelesin in untreated metastatic breast cancer 1998 ·Anti-Cancer Drugs ·Massimo Cristofanilli,William J. Bryan,Langdon L. Miller,Alex Y. C. Chang,William J. Gradishar,Donald Küfe,Gabriel N. Hortobagyi	30
17	Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells 1996 ·Journal of Immunotherapy ·Brendan D. Curti,Augusto C. Ochoa,Walter J. Urba,W. Gregory Alvord,William C. Kopp,(unknown),(unknown),Stephen P. Creekmore,Barry L. Gause,John E. Janik,Jon Holmlund,(unknown),Robert G. Fenton,Langdon L. Miller,Mario Sznol,John W. Smith,William H. Sharfman,Dan L. Longo	17
18	Endocrine Effects of IL-1α and β Administered in a Phase I Trial to Patients with Advanced Cancer 1996 ·Journal of Immunotherapy ·Brendan D. Curti,Walter J. Urba,Dan L. Longo,John E. Janik,William H. Sharfman,Langdon L. Miller,Giovanni Cizza,Masanao Shimizu,Joost J. Oppenheim,W. Gregory Alvord,John W. Smith	17
19	The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin 1993 ·New England Journal of Medicine ·John W. Smith,(unknown),W. Gregory Alvord,John E. Janik,William H. Sharfman,Barry L. Gause,Brendan D. Curti,(unknown),Jon Holmlund,(unknown),Mario Sznol,Langdon L. Miller,Masanao Shimizu,Joost J. Oppenheim,(unknown),(unknown),(unknown),Walter J. Urba	98
20	Stopping a clinical trial very early because of toxicity: Summarizing the evidence 1993 ·Controlled Clinical Trials ·Edward L. Korn,Kai Yu,Langdon L. Miller	8

About Langdon L. Miller

Langdon L. Miller is a scholar working on Genetics, Oncology and Hematology, having authored 65 papers that have together received 7.6k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (19 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lung Cancer Research Studies (10 papers). The work is most often cited by research in Genetics (1.8k citations), Oncology (4.0k citations) and Hepatology (1.0k citations). Langdon L. Miller has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Gary Elfring, Paula K. Locker, Nicoletta Pirotta, Leonard B. Saltz, John V. Cox, Stephen P. Ackland, Lee S. Rosen, Charles D. Blanke, Jean A. Maroun and Malcolm J. Moore. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact